Efficacy and safety of TMC125 (etravirine) in treatment-experienced hiv-1-infected patients in DUET-1 : 24-week results from a randomised, double-blind, placebo-controlled trial. Commentary

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 370; no. 9581
Main Authors HIRSCHEL, Bernard, PERNEGER, Thomas, PEETERS, Monika, VINGERHOETS, Johan, DE SMEDT, Goedele, LEOPOLD, Lorant, TREFIGLIO, Roberta, WOODFALL, Brian, LOZZARIN, Adriano, CAMPBELL, Thomas, CLOTET, Bonaventura, JOHNSON, Margaret, VALDEZ MADRUGA, José, KATLAMA, Christine, MOLL, Arend, TOWNER, William, TROTTIER, Benoit, PEETERS, Moniko, BAETEN, Benny, BEETS, Greet, SINHA, Rekha, CAHN, Pedro, BERGER, Daniel, MCMURCHIE, Marilyn, SUTER, Fredy, BANHEGYI, Denes, RUXRUNGTHAM, Kiat, NOMS, Dorece, LEFEBVRE, Eric, DE BETHUNE, Marie-Pierre, TOMAKA, Frank, GRINSZTEJN, Beatriz, DE PAUW, Martine, VANGENEUGDEN, Tony, SPINOSA-GUZMAN, Sabrina, HAUBRICH, Richard, LALEZARI, Jacob, MILLS, Anthony, PIALOUX, Gilles, WILFEIN, Timothy
Format Journal Article
LanguageEnglish
Published London Lancet 2007
Subjects
Biological and medical sciences
General aspects
Human viral diseases
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Medical sciences
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Immunopathology
Toxicity
Non nucleoside compound
AIDS
Immune deficiency
Result
Infection
Medicine
Treatment
Viral disease
Etravirine
Double blind study
Antiviral
Clinical trial
Safety
Online AccessGet full text

Cover

More Information
ISSN:0140-6736
1474-547X